Intuitive Surgical's Q3 earnings hinge on robotic surgery growth, system demand and margins amid slowing US procedures, China headwinds and premium valuation.
Intuitive Surgical, Inc. (ISRG) reached $427.86 at the closing of the latest trading day, reflecting a +1.81% change compared to its last close.
Evaluate the expected performance of Intuitive Surgical (ISRG) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Intuitive Surgical shares have surged nearly 12% in a month ahead of Q3 earnings. Strong da Vinci 5 adoption and Ion growth fuel momentum, but valuation and risks linger.
Intuitive Surgical is targeting GI care with a next-generation robotic endoscope submitted to the FDA, opening a potential growth avenue beyond surgery.
Intuitive Surgical (ISRG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $423.96, signifying a +2.06% move from its prior day's close.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Intuitive Surgical, Inc. (ISRG) reached $414.52 at the closing of the latest trading day, reflecting a +2.41% change compared to its last close.
Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.
Intuitive Surgical remains a wide-moat leader in robotic surgery with strong secular tailwinds and high recurring revenue potential. ISRG's installed base and utilization rates offer significant runway for growth, supported by product innovation and expansion into new markets. Despite a compression in valuation multiples, ISRG's forward P/E remains attractive given its historical premium and robust growth prospects.